SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

NEXT STORY
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity
PREV STORY
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

CRO Regulatory Services for Generics and Biosimilars Drugs Market Report 2020-2030

author_avatar
NASDAQ Market News

Sports Medicine Market USD 9,655.6 Mn Revenue Expected by 2023 | Increasing Awareness on Sports Injury to Drive Bright Future

Market Research Future has released Premium Research Report titled “Global Sports Medicine Market Forecast ...

author_avatar
NASDAQ Market News

aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications

author_avatar
NASDAQ Market News